Conclusion
Drug developers and practitioners alike can use the change in one
logarithm of effect size as a benchmark to decide if further testing in
RCTs should be pursued, or as a guide to interpreting the results
reported in non-randomized studies. However, further research would be
useful to better characterize the threshold of effect size above which
testing in RCTs is not needed.